TORONTO, Jan. 13, 2015 (GLOBE NEWSWIRE) -- Pursuant to its news release of August 07, 2014, Gemoscan Canada, Inc. (TSX-V:GES) (MUN:1GE) ("Gemoscan" or the "Company"), is pleased to announce that it has established a wholly owned subsidiary, Hemocode USA, Inc., ("HUI") through which to sell and market its HemocodeTM and other leading food sensitivity management programs. HUI has been set up under the laws of the state of Delaware.

In addition, Gemoscan is pleased to announce that one of its key valued added resellers has, through a convertible debenture issued by HUI, taken an option to acquire a minority interest in HUI.

Dr. Brian Wolfs D.C., a principal of the entity that provided the initial financing to HUI, has been appointed as a director of HUI and has been granted 200,000 options in the Company priced at $0.05 per share for a period of five years.

The HemocodeTM System, like the Company's other programs, is a personalized medically supervised nutritional program that promotes dietary well being. It uses portions of Gemoscan's patented technology, and proprietary services to provide consultation and recommendations intended to simplify the management of food sensitivities. Today, HemocodeTM is offered by over 600 pharmacies and medical clinics across Canada as a complementary medical choice. The Company's food sensitivity management programs are used as adjuncts in conventional and complementary medical practices, incorporating modalities and therapies that focus on lifestyle and wellness. A statistically significant base of practitioners and those engaging with HemocodeTM have reported improved dietary and overall wellness satisfaction.

Gemoscan expects that HemocodeTM will now be available in select U.S markets during the first quarter of 2015.

About Gemoscan Canada, Inc.

Gemoscan is an industry leader in food intolerance management and maintains a first-to-market position with Canada wide distribution through select retail partners. Founded in 2003, using its proprietary patented technology, Gemoscan develops, owns and markets comprehensive naturopathic dietary management solutions for consumers, including the HemocodeTM System and the MenuWise™ Plan, personalized medically supervised programs that promote dietary well-being. Gemoscan is the first and only provider to commercialize a food sensitivity management solution directly to consumers in partnership with retailers, and today offers the most comprehensive services available. Gemoscan also owns and operates multidisciplinary paramedical clinics, located in Toronto, Ontario.

Gemoscan Canada, Inc. trades its shares on the Toronto Venture Exchange under the symbol GES and is quoted on the Munich, Frankfurt and Stuttgart Stock Exchanges under the symbol 1GE.

Forward-Looking Information

This news release contains certain "forward-looking information". All statements, other than statements of historical fact that address activities, events or developments that Gemoscan believes, expects or anticipates will or may occur in the future. These forward-looking statements reflect the current expectations or beliefs of Gemoscan based on information currently available to Gemoscan. Forward-looking statements are subject to a number of significant risks and uncertainties and other factors that may cause the actual results of Gemoscan to differ materially from those discussed in the forward-looking statements, and even if such actual results are realized or substantially realized, there can be no assurance that they will have the expected consequences to, or effects on Gemoscan. Any forward-looking statement speaks only as of the date on which it is made and, except as may be required by applicable securities laws, Gemoscan disclaims any intent or obligation to update any forward-looking statement, whether as a result of new information, future events or results or otherwise. Although Gemoscan believes that the assumptions inherent in the forward-looking statements are reasonable, forward-looking statements are not guarantees of future performance and accordingly undue reliance should not be put on such statements due to the inherent uncertainty therein.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For more information please contact:

Company:
Brian Kalish
Chief Executive Officer
Gemoscan Canada, Inc.

Tel: 416.650.1200

www.gemoscan.com